Aspen Neuroscience Advances Parkinson's Treatment Through Recent Clinical Trials
Aspen Neuroscience Progresses with Parkinson's Disease Treatment
Overview
Aspen Neuroscience, Inc., a pioneering biotech company focused on regenerative medicine, has recently completed dosing for the third and fourth cohorts in its ongoing Phase 1/2a clinical trial named ASPIRO. This trial evaluates the effectiveness of sasineprocel (ANPD001) in treating Parkinson's disease (PD). By reaching this milestone, Aspen is making significant strides in the development of personalized, autologous cell therapies aimed at combating this debilitating condition.
Clinical Trial Details
The ASPIRO study has now dosed a total of 15 patients, marking one of the most extensive clinical experiences with autologous cell therapy in the context of Parkinson's disease. This is particularly noteworthy when considering the growing interest and investment in cell therapies that use a patient's own cells.
Cohorts 3 and 4 utilized Aspen's commercial-ready formulation of sasineprocel, which is designed for scalability and reproducibility in manufacturing and clinical application. This formulation employs a **cryopreserved
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.